Clinical Trials Logo

Filter by:
NCT ID: NCT06318377 Recruiting - Healthy Clinical Trials

Peanuts and Neurocognitive / Cardiovascular Health in Black Individuals

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The overall research objective of this proposal is to determine the impact of increased daily peanut consumption on indices of neurocognitive and physiological health in BL individuals

NCT ID: NCT06318338 Recruiting - Cancer Clinical Trials

Virtual Reality to Promote Relaxation Prior to Simulation

Start date: April 8, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the feasibility of a pre-simulation virtual reality (VR) platform designed to promote relaxation for cancer patients planned for radiation therapy (RT).

NCT ID: NCT06318273 Recruiting - Clinical trials for Metastatic Castration-Resistant Prostate Cancer

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

Start date: March 8, 2024
Phase: Phase 1
Study type: Interventional

Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and efficacy of ABBV-969 as a monotherapy. ABBV-969 is an investigational drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are parts to this study. Participants will receive ABBV-969 as a single agent at different doses. Approximately 120 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), ABBV-969 will be intravenously infused in escalating doses as a monotherapy. In part 2, multiple doses will be selected from Part 1 and mCRPC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. The estimated duration of the study is up to 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

NCT ID: NCT06318169 Recruiting - Clinical trials for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Start date: March 13, 2024
Phase: Phase 3
Study type: Interventional

The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis [NASH]).

NCT ID: NCT06317701 Recruiting - Clinical trials for Obstructive Sleep Apnea

Metabolic Endpoints for Obstructive Sleep Apnea Following Twelfth Cranial Nerve Stimulation

Start date: April 4, 2024
Phase:
Study type: Observational

The purpose of this study is to determine if the treatment of Obstructive sleep apnea (OSA) by hypoglossal nerve stimulation (HGNS) will alter glucose metabolism. The study team will also determine if the treatment of Obstructive sleep apnea (OSA) by (hypoglossal nerve stimulation) HGNS will alter predictors of cardiovascular outcomes.

NCT ID: NCT06317649 Recruiting - Clinical trials for Acute Myeloid Leukemia

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Start date: March 3, 2025
Phase: Phase 2
Study type: Interventional

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.

NCT ID: NCT06316973 Recruiting - Clinical trials for Substance Use Disorders

A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants

Start date: February 7, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.

NCT ID: NCT06316843 Recruiting - Long COVID Clinical Trials

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

PASC
Start date: October 15, 2023
Phase: Phase 2
Study type: Interventional

To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19.

NCT ID: NCT06316804 Recruiting - Depression Clinical Trials

Mobile Mental Health Stigma Reduction Intervention Among Black Adults

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

Major depressive and anxiety disorders are highly prevalent in the general population and are a leading cause of disability. Black adults have a high burden of depression and anxiety. This study aims to assess a self- administered video-based intervention to reduce mental illness stigma and medical mistrust among Black adults with moderate to severe depression or anxiety.

NCT ID: NCT06316713 Recruiting - Chronic Pain Clinical Trials

One MORE for Chronic Pain in Latinos

Start date: April 8, 2024
Phase: N/A
Study type: Interventional

This study will be a single-site, two-arm randomized controlled trial conducted among Spanish-speaking chronic pain patients. Chronic pain patients will be randomized by a computer-generated randomization schedule with simple random allocation (1:1) to either One MORE or a wait-list control condition (WLC). One MORE will be delivered individually either in-person or via a HIPAA compliant virtual meeting platform.